自定内容

Search
 
 
Product Details
Abiraterone,abiraterone
Abiraterone
Abiraterone,abiraterone acetate(CAS:154229-19-3) is a drug used in castration-resistant prostate cancer

Name

Abiraterone

CAS

154229-19-3

Synonyms

17-(3-Pyridyl)androsta-5,16-dien-3beta-ol;CB 7598;Androsta-5,16-dien-3-ol,17-(3-pyridinyl)-, (3b)-;

MF

C24H31NO

MW

349.51

Others

It is indicated for use as a treatment for prostate cancer.[3][4][5][6] It has received FDA (28 April 2011), EMA (23 September 2011), MHRA (5 September 2011) and TGA (1 March 2012) approval for this indication.[3][4][5][6] In Australia it is covered by the Pharmaceutical Benefits Scheme when being used to treat castration-resistant prostate cancer and given in combination with prednisone/prednisolone (subject to the conditions that the patient is not currently receiving chemotherapy, they are either resistant or intolerance of docetaxel, have a WHO performance status of <2 and their disease has not since become progressive since treatment with PBS-subsidised abiraterone has commenced).[7]

 

 
 
Enter your keywords